Bremelanotide (PT-141)
PT-141, Vyleesi. Cyclic heptapeptide melanocortin receptor agonist. FDA-approved for HSDD in women (Vyleesi). Activates MC3R and MC4R in CNS to increase sexual arousal.
Member access required
Clinical protocols and outcomes data are available to AXIFI Members and Providers.